Innovative Solutions for Better Health

 

Cancer is our Focus

About 78% of all cancer is detected in people 55 and older.  In their lifetime, men have slightly less than a 1 in 2 risk of developing cancer, while women have a little more than a 1 in 3 risk.  The National Cancer Institute estimates that as of January 2006 approximately 11.4 million Americans had a history of cancer (The American Cancer Society).

Work at Mor-NuCo LLC is focused on development of the first universal test that not only detects cancer early but also discriminates among all forms of human cancer.  The test will help oncologists monitor therapy and diagnose cancer sooner to allow for much earlier intervention than is now possible.

Mor-NuCo LLC will commercialize a specific protein marker of the cancer cell surface that provides for early detection of cancer, better monitoring of cancer treatment and improved early intervention as a prevention-oriented approach to cancer management under the service mark ONCOblotSM.  The company has secured two licensed patents involving the marker protein which is vital to the unregulated growth of cancer cells.

Drs. D. James and Dorothy M. Morré, Professors emeriti of Purdue University are the company’s founders and principal investors.  The Morré’s have dedicated the past 30 years of their careers to unlocking the mechanisms responsible for the unregulated growth of cancer cells.  A cell-surface protein known as ECTO-NOX2 (ENOX2), critical to tumor formation, is the marker protein targeted for the early cancer detection and intervention strategies under development.

ENOX2 Research

ENOX2 proteins are growth related, cell surface transcript variant proteins expressed and shed into the blood specifically by cancer cells.

These cell surface proteins serve as specific markers for early cancer detection and as indicators of organ site of cancer origin.

The proteins also provide an excellent opportunity to serve as targets for early intervention and treatment of cancer.

CAPSOL-T® Research

Capsol-T® is an all-natural product targeted to ENOX-2 cancer proteins causing cancer cell death by apoptosis.  This, in turn, prevents the growth the cancer.

 

MOR-NuCo LLC

Purdue Research Park
1291C Cumberland Avenue
West Lafayette, IN 47906
Phone:  765-464-1583
Fax:  765-464-8769
Email: davidg@mornuco.com

 

Traveling to Mor-NuCo

Directions from Chicago (approx. travel time 2 hours)

  1. I-90 to I-65.
  2. Stay on I-65 for approximately 70 miles
  3. Take exit 193 for US-231 toward Wolcott/Chalmers.
  4. Follow US-231 S for about 14 miles.
  5. Turn left on to US-52 E/US-231 S.
  6. Follow US-52 E/US-231 S for approximately 5.5 miles
  7. Turn left on to Cumberland Ave.
  8. Continue through the roundabout on Cumberland Ave.
  9. Take the first immediate right after the roundabout and enter the Business and Technology Center
  10. Mor-NuCo is on the back side, entrance C

Directions from Indianapolis (approx. travel time 1 hour 15 minutes)

  1. Take I-65 north toward Chicago.
  2. Stay on I-65 for approximately 55 miles.
  3. Exit 175, turn south/left onto S.R. 25. Stay right.
  4. Intersection of S.R. 25 and US 52 turn west/right.
  5. Stay on U.S. 52 through 4 stop lights.
  6. The 5th light will be the intersection of U.S. 52 and Cumberland Ave.
  7. Turn right.
  8. Once on Cumberland Ave., go through the roundabout staying on Cumberland Ave.
  9. Take the first immediate right after the roundabout and enter the Business and Technology Center
  10. Mor-NuCo is on the back side, entrance C